DUAL Antithrombotic Therapy in Patients With AF and ACS
Status:
Unknown status
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
The study aims to show inferiority of rivaroxaban plus ticagrelor when compared to
rivaroxaban plus clopidogrel in terms of safety. Safety will be determined by comparing the
rates of death or ischemic event-including myocardial infarction, definite or probable stent
thrombosis, stroke, or urgent revascularization.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University